CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.7200
-0.0100 (-1.37%)
At close: Apr 1, 2025, 4:00 PM
0.7223
+0.0023 (0.32%)
After-hours: Apr 1, 2025, 4:40 PM EDT
CERO Employees
As of December 31, 2023, CERo Therapeutics Holdings had 9 total employees, including 8 full-time and 1 part-time employees.
Employees
9
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$609,795
Market Cap
1.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CERO News
- 1 day ago - CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors - GlobeNewsWire
- 5 days ago - CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing - GlobeNewsWire
- 13 days ago - CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - GlobeNewsWire
- 19 days ago - CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting - GlobeNewsWire
- 26 days ago - CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays - GlobeNewsWire
- 27 days ago - CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14 - GlobeNewsWire
- 7 weeks ago - CERo Therapeutics Holdings, Inc. Highlights Progress - GlobeNewsWire
- 7 weeks ago - CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire